Cargando…

COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England

Detalles Bibliográficos
Autores principales:	Kirsebom, Freja C M, Andrews, Nick, Stowe, Julia, Toffa, Samuel, Sachdeva, Ruchira, Gallagher, Eileen, Groves, Natalie, O'Connell, Anne-Marie, Chand, Meera, Ramsay, Mary, Bernal, Jamie Lopez
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9129256/ https://www.ncbi.nlm.nih.gov/pubmed/35623379 http://dx.doi.org/10.1016/S1473-3099(22)00309-7

Ejemplares similares

Effectiveness of the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in England
por: Møller Kirsebom, Freja Cordelia, et al.
Publicado: (2022)

Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England
por: Kirsebom, Freja Cordelia Møller, et al.
Publicado: (2022)

Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England
por: Andrews, Nick, et al.
Publicado: (2022)

Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021–March, 2022: a national, observational, test-negative, case-control study
por: Powell, Annabel A, et al.
Publicado: (2023)

Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study
por: Stowe, Julia, et al.
Publicado: (2022)

Effectiveness of BNT162b2 against COVID-19 in adolescents
por: Powell, Annabel A, et al.
Publicado: (2022)

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
por: Andrews, Nick, et al.
Publicado: (2022)

Monitoring the COVID-19 immunisation programme through a national immunisation Management system – England’s experience
por: Tessier, Elise, et al.
Publicado: (2023)

Risk of severe outcomes among SARS-CoV-2 Omicron BA.4 and BA.5 cases compared to BA.2 cases in England
por: Abdul Aziz, Nurin, et al.
Publicado: (2023)

Durability of AZD1222 and hybrid humoral immunity against omicron BA.1 and BA.4
por: Soto-Rifo, Ricardo
Publicado: (2023)

Effectiveness of BNT162b2 and ChAdOx-1 vaccines in residents of long-term care facilities in England using a time-varying proportional hazards model
por: Paranthaman, Karthik, et al.
Publicado: (2022)

Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England
por: Webster, H. H., et al.
Publicado: (2022)

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines
por: Andrews, Nick, et al.
Publicado: (2022)

High attack rate in a large care home outbreak of SARS-CoV-2 BA.2.86, East of England, August 2023
por: Reeve, Lucy, et al.
Publicado: (2023)

Real-world effectiveness of nirmatrelvir–ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants
por: Wong, Carlos K H, et al.
Publicado: (2023)

Pathogenicity of SARS-CoV-2 Omicron BA.1.1 in hamsters
por: Chan, Jasper Fuk-Woo, et al.
Publicado: (2022)

Genomic surveillance of SARS-CoV-2 upsurge in India due to Omicron sub-lineages BA.2.74, BA.2.75 and BA.2.76
por: Singh, Urvashi B., et al.
Publicado: (2023)

Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2
por: Vasin, Andrey V, et al.
Publicado: (2023)

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
por: Lopez Bernal, Jamie, et al.
Publicado: (2021)

Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England
por: Harman, Katie, et al.
Publicado: (2023)

Twin peaks: The Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England
por: Elliott, Paul, et al.
Publicado: (2022)

Omicron severity: milder but not mild
por: Nealon, Joshua, et al.
Publicado: (2022)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study
por: Hall, Victoria Jane, et al.
Publicado: (2021)

Omicron in pregnancy: time to breathe easier?
por: Auger, Nathalie, et al.
Publicado: (2022)

Effectiveness of BNT162b2 and ChAdOx1 against SARS-CoV-2 household transmission: a prospective cohort study in England
por: Clifford, Samuel, et al.
Publicado: (2023)

Omicron infection milder in nursing home residents
por: Katz, Morgan J, et al.
Publicado: (2022)

Prioritisation of COVID-19 boosters in the omicron era
por: Irving, Stephanie A, et al.
Publicado: (2022)

All-cause excess mortality observed by age group and regions in the first wave of the COVID-19 pandemic in England
por: Sinnathamby, Mary A, et al.
Publicado: (2020)

Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: A national cohort study in England
por: Andrews, Nick J, et al.
Publicado: (2021)

Milder disease with Omicron: is it the virus or the pre-existing immunity?
por: Sigal, Alex
Publicado: (2022)

Omicron: fewer adverse outcomes come with new dangers
por: Post, Lori Ann, et al.
Publicado: (2022)

Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England
por: Strasser, Zachary H., et al.
Publicado: (2022)

Omicron breakthrough infections in patients with immune-mediated inflammatory diseases
por: Liew, Jean W, et al.
Publicado: (2022)

Effectiveness of mRNA booster doses against the omicron variant
por: Zedan, Hadeel T, et al.
Publicado: (2022)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period
por: Boekel, Laura, et al.
Publicado: (2022)

COVID-19 vaccine boosters in the Asia-Pacific region in the context of Omicron
por: Hart, John D, et al.
Publicado: (2022)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

Estimating disease severity of Omicron and Delta SARS-CoV-2 infections
por: Sigal, Alex, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c8rruklkhsg7fh4m3l9vc52uga